<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Long-term <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy was changed to subcutaneous <z:chebi fb="5" ids="28304">heparin</z:chebi> to cover a planned pregnancy in a patient with congenital antithrombin III (AT III) deficiency </plain></SENT>
<SENT sid="1" pm="."><plain>Satisfactory anticoagulation was easily maintained in spite of low levels of biologically active AT III </plain></SENT>
<SENT sid="2" pm="."><plain>Delivery and the puerperium were covered by a reduced dose of <z:chebi fb="5" ids="28304">heparin</z:chebi> and alternate day infusions of AT III concentrate </plain></SENT>
<SENT sid="3" pm="."><plain>A mean dose of 0.77 U/kg of AT III concentrate produced a rise of 1% in AT III and the half-life was of the order of 24 h, with no evidence of increased consumption during labour and delivery </plain></SENT>
<SENT sid="4" pm="."><plain>Pregnancy and labour were uncomplicated and resulted in delivery of a healthy female infant </plain></SENT>
<SENT sid="5" pm="."><plain>The importance of early and adequate anticoagulation during pregnancy is emphasized </plain></SENT>
</text></document>